Pharmacological characterisation of purinergic receptors that mediate NFAT activation. A, Effects of purinergic agonists. Cells were treated with the indicated compounds at the following final concentrations: 300 μM ATP, 300 μM UTP, 30 μM α,β-MeATP, 30 μM BzATP or 10 μM calcimycin + 1 μM PMA. Ø, untreated control cells. B, Effect of the P2X antagonist PPADS. PC12-pNFAT-Luc cells were treated with ATP and PPADS as indicated before the cells were lysed, and luciferase activity was measured. Luciferase activities are expressed as the fold stimulation by the treatment relative to that in cells treated with 300 μM ATP alone. Data are shown as mean ± SD of 4 independent experiments except for Calc+PMA (n = 3). Statistical significance is indicated for differences vs. control (panel A) or vs. 300 μM ATP (panel B) **, p < 0.01; ***, p < 0.001.
Prasai et al. BMC Neuroscience 2011 12:90 doi:10.1186/1471-2202-12-90